Going forward..., page-1196

"In addition, the license option agreement includesa) an option to negotiate a licence for manufacturing CYP-001 product andb) certain rights to Cynata’s proprietary Cymerus technology for the prevention and treatment ofother diseases.Exercise of the rights to these additional components attracts further fees."
I bet Fuji has a comprehensive balance sheet that tells it what the tipping point is for making a t/o rather than than making ongoing payments under different licencing scenarios. Unfortunately, only they know what these different scenarios are.
Did I read somewhere that of 800+ potential diseases CYP had identified 100+ for which its technology could be a solution?
That is a LOT of fees & royalties!